Biodexa Pharmaceuticals Plc Overview
Pro stress-test →Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing a pipeline of products for the treatment of diseases with unmet medical needs. The company's lead development programme, eRapa, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is bowel resection.
Strategic Profile
Pro stress-test →The company's pipeline includes tolimidone under development for type 1 diabetes, and MTX110 being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months.
Competitive Landscape
Pro stress-test →Biodexa competes in oncology and rare disease biotech against larger established companies with broader pipelines. Primary competitors include sponsors of mTOR inhibitors (Novartis, Pfizer) in oncology, and type 1 diabetes developers (Eli Lilly, Novo Nordisk). In rare brain cancers and drug delivery, Biodexa's Q-Sphera and MidaCore platforms differentiate against generic competitors, though it lacks the scale and resources of major pharma.
Industry Context
Biodexa Pharmaceuticals Plc operates in Oncology Drugs.
Key facts
Founded: Unknown; incorporated as UK-listed biotech · Headquarters: Halesowen, United Kingdom · Employees: Unknown · Revenue: Pre-revenue (clinical stage); estimated operating burn approximately $5-10M annually based on typical Stage biotech profiles · Market cap: Approximately $1.6M (as of July 27, 2026)